RU2012148909A - Новый синтез соединений тиазолидиндиона - Google Patents

Новый синтез соединений тиазолидиндиона Download PDF

Info

Publication number
RU2012148909A
RU2012148909A RU2012148909/04A RU2012148909A RU2012148909A RU 2012148909 A RU2012148909 A RU 2012148909A RU 2012148909/04 A RU2012148909/04 A RU 2012148909/04A RU 2012148909 A RU2012148909 A RU 2012148909A RU 2012148909 A RU2012148909 A RU 2012148909A
Authority
RU
Russia
Prior art keywords
thiazolidindione
compounds
new synthesis
compound
formula
Prior art date
Application number
RU2012148909/04A
Other languages
English (en)
Inventor
Тимоти ПАРКЕР
Роберт К. ГЭДВУД
Стивен П. ТАНИС
Скотт Д. ЛАРСЕН
Джеймс Р. ЗЕЛЛЕР
Original Assignee
МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи filed Critical МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи
Publication of RU2012148909A publication Critical patent/RU2012148909A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

1. Соединение, имеющее формулу:или его соль.2. Гидробромидная соль соединения, имеющего формулу:

Claims (2)

1. Соединение, имеющее формулу:
Figure 00000001
или его соль.
2. Гидробромидная соль соединения, имеющего формулу:
Figure 00000001
RU2012148909/04A 2010-04-19 2011-04-18 Новый синтез соединений тиазолидиндиона RU2012148909A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32552810P 2010-04-19 2010-04-19
US61/325,528 2010-04-19
PCT/US2011/032816 WO2011133441A2 (en) 2010-04-19 2011-04-18 Novel synthesis for thiazolidinedione compounds

Publications (1)

Publication Number Publication Date
RU2012148909A true RU2012148909A (ru) 2014-05-27

Family

ID=44041528

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012148909/04A RU2012148909A (ru) 2010-04-19 2011-04-18 Новый синтез соединений тиазолидиндиона

Country Status (10)

Country Link
US (2) US20130211095A1 (ru)
EP (1) EP2563767A2 (ru)
JP (1) JP2013532121A (ru)
KR (1) KR20130051944A (ru)
CN (1) CN103153972A (ru)
AU (1) AU2011242955A1 (ru)
CA (1) CA2796872A1 (ru)
MX (1) MX2012012094A (ru)
RU (1) RU2012148909A (ru)
WO (1) WO2011133441A2 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
CN102947269B (zh) 2010-04-19 2015-11-25 新陈代谢解决方案开发公司 噻唑烷二酮化合物的新的合成方法
JP5851506B2 (ja) 2010-08-10 2016-02-03 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー チアゾリジンジオン化合物のための合成
JP5927190B2 (ja) * 2010-08-10 2016-06-01 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー チアゾリジンジオン化合物のための新規合成
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US10326748B1 (en) 2015-02-25 2019-06-18 Quest Software Inc. Systems and methods for event-based authentication
US10417613B1 (en) 2015-03-17 2019-09-17 Quest Software Inc. Systems and methods of patternizing logged user-initiated events for scheduling functions
US10536352B1 (en) 2015-08-05 2020-01-14 Quest Software Inc. Systems and methods for tuning cross-platform data collection
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK109993A3 (en) * 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
SE9702305D0 (sv) * 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
AU2007227581B2 (en) * 2006-03-16 2012-11-08 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
NZ571870A (en) * 2006-03-16 2011-07-29 Metabolic Solutions Dev Co Thiazolidinedione analogues for the treatment of hypertension and for lowering lipids
JP2009013091A (ja) * 2007-07-03 2009-01-22 Tokuyama Corp ピオグリタゾン塩酸塩の製造方法

Also Published As

Publication number Publication date
AU2011242955A1 (en) 2012-11-01
CA2796872A1 (en) 2011-10-27
MX2012012094A (es) 2012-12-17
US20130211095A1 (en) 2013-08-15
WO2011133441A3 (en) 2015-09-17
JP2013532121A (ja) 2013-08-15
WO2011133441A2 (en) 2011-10-27
EP2563767A2 (en) 2013-03-06
KR20130051944A (ko) 2013-05-21
CN103153972A (zh) 2013-06-12
US20140018542A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
RU2012148909A (ru) Новый синтез соединений тиазолидиндиона
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
JP2012111758A5 (ru)
RS54386B1 (en) ANTIVIRAL UNITS
RS54730B1 (sr) Inhibitori beta sekretaze
RS54207B1 (en) CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
UA107791C2 (en) Pesticidal compositions
CY1112722T1 (el) Μυκητοκτονες συνθεσεις
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
CR20110432A (es) Pirimidinas fusionadas
RS52255B (en) NALMEFEN HYDROCHLORIDE DIHYDRATE
RS53003B (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
RS54488B1 (en) NALOXOL-POLYETHYLENE GLYCOL CRYSTAL CONJUGATE
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
AU2012310674B2 (en) Radioactive fluorine labeled compound
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
RU2009101579A (ru) Мономер для поликонденсации
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
RU2008151868A (ru) Мономер для поликонденсации
GB201020397D0 (en) Compounds
RU2011118463A (ru) Ароматические блок-сополиэфиркетоны
RU2010143923A (ru) Ненасыщенные блок-сополиэфирсульфоны
RU2010119316A (ru) Поли - n, n- диаллиламиноэтановая кислота
EA201690593A1 (ru) Новые соединения мочевины
RS53747B1 (en) FENANTRENON UNITS, COMPOSITIONS AND METHODS

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20140421